The Inpatient Management of Anticoagulation for Patients with Atrial Fibrillation

Expert Panelist Lead: Ian Jenkins MD and Scott Kaatz DO, MSC, FACP, FHM 

Accreditation and Designation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Blackwell Futura Media Services and the Society of Hospital Medicine Blackwell Futura Media Services is accredited by the ACCME to provide continuing medical education for physicians.”

Blackwell Futura Media Services designates this enduring material for a maximum of (1 CREDIT) AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Educational Objectives

Upon completion of this educational activity, participants will be better able to: 

The need for this educational activity is to inform hospitalists and pharmacists on ways to improve inpatient anticoagulation management with a focus on best practices and methods to ‘hard wire’ these outline processes so they have a large positive impact on the quality and safety of patient care.  

Series List

Activity 1 – Management of Target Specific Oral Anticoagulants (TSOACs) in the Inpatient and Perioperative Setting

Activity 2 – The Inpatient Management of Anticoagulation for Patients with Atrial Fibrillation

Activity 3 – Anticoagulation for VTE & Management of VTE Part I

Activity 4 – Anticoagulation for VTE & Management of VTE  Part II

Activity 5 – Reversal of New Oral Anticoagulants

Activity 6 – Establishing Inpatient Programs to Improve Anticoagulation Management

Activity 7 – Periprocedural Management of Anticoagulants

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-physician
Course opens: 
11/16/2014
Course expires: 
11/16/2017
Non-member cost:
$0.00
Parent activity set: 
Rating: 
0

This activity is supported by an educational grant from Daichii Sankyo, Inc. 


Expert Panelist Lead: Ian Jenkins MD- University of California, San Diego, CA has no conflicts of interest to disclose

Expert Panelist: Allison Burnett PharmD, PhC, CACP- University of New Mexico, Albuquerque, NM has no conflicts of interest to disclose

Expert Panelist: Margaret Fang MD- University of California, San Fransico, CA has no conflicts of interest to disclose

Expert Panelist Lead: Scott Kaatz DO, MSC, FACP, FHM-  Hurley Medical Center, Flint, MI) 

•       Grant support (to institution)

–      Boehringer Ingelheim

–      Bristol-Myers Squibb

–      Janssen

–      Eisai

–      Iverson Genetic Diagnostics/Medicare

–      National Institutes of Health

–      Canadian Institutes of Health Research

–      Blue Cross/Blue Shield of Michigan

•       Speaker honorarium

–      Janssen

–      Boehringer Ingelheim

–      Bristol-Myers Squibb/Pfizer

–      CSL Behring

•       Consultant

–      Boehringer Ingelheim

–      Bristol-Myers Squibb/Pfizer

–      Janssen

–      Daiichi Sankyo

•       Board membership (non-profit)

–      Anticoagulation Forum

–      Thrombosis and Hemostasis Societies of North America

–      National Certification Board for Anticoagulation Providers

–      National Blood Clot Alliance Medical Scientific Advisory Board

SHM complies with ACCME Standards for Commercial Support by following policies and procedures designed to identify and manage conflicts of interest in Company-supported Society CME programs at all stages in program design and implementation. All programs are developed independent of any sponsor input and do not allow the use of trade names. Furthermore, SHM instructs faculty to present a balanced view of treatment options and reviews material to make sure this is the case. SHM is transparent about all funding received. 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
11/16/2014
Course expires: 
11/16/2017

Price

Non-member cost:
$0.00
Please login or register to take this course.